Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RR110 in Active Crohn's Disease
NCT00417391Phase 2Completed
- Sponsor
- R & R Group
- Start
- Dec 2006
- Primary completion
- May 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised trial of tamibarotene in Crohn's disease (2 arms), sponsored by R & R Group. Primary endpoint: Change in Crohn's Disease Activity Index at 8 weeks. Started Dec 2006; status: completed.
02
Drugs
tamibarotene
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00417391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00417391.